Real-world and switching evidence
What published studies report when patients move from a reference product to a biosimilar, or from one biosimilar to another, molecule by molecule.
Molecules
Adalimumab23
studies: 7 with repeated switching, 7 with a single switch, 9 from routine careOpenInsulin glargine1
study: 1 with repeated switchingOpenUstekinumab2
studies: 1 with repeated switching, 1 from routine careOpenRituximab3
studies: 1 with a single switch, 2 from routine careOpenInfliximab22
studies: 9 with a single switch, 13 from routine careOpenEtanercept8
studies: 1 with repeated switching, 3 with a single switch, 4 from routine careOpenRanibizumab2
studies: 2 with a single switchOpenFilgrastim1
study: 1 with repeated switchingOpenEculizumab2
studies: 2 with a single switchOpenEvySaif prepares interchangeability and switching dossiers and designs real-world studies for biosimilar programmes. Regulatory strategy consulting
Need switching evidence for your market?
EvySaif can assess the evidence available for your product, design the study that fills the gap and prepare the dossier that carries it.
Talk to a biosimilar regulatory consultantData current to September 2026.